glp-1 regain weight The Gap Between Prescriptions and Persistence Quitting GLP-1 drugs triggers rapid

melanocortin receptor research, pigmentation pathway models, MT-1/MT-2 comparison studies

Because Medicare coverage rules have not been formally amended, CMS plans to rely on two demonstration authorities to implement this expansion

Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial

Disclosure forms provided by the authors are available with the article at ugeskriftet.dk/dmj References can be found with the article at ugeskriftet.dk/dmj Cite this as Dan Med J 2025;72(5):A09240629 doi 10.61409/A09240629 Open Access under Creative Commons License CC BY-NC-ND 4.0 Referencer Ortved M, Petersen PB, Jrgensen CC et al